Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lisata Therapeutics, Inc. - Common Stock (NQ:LSTA)

1.970 -0.090 (-4.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 41,077
Open 1.950
Bid (Size) 1.970 (600)
Ask (Size) 1.980 (100)
Prev. Close 2.060
Today's Range 1.950 - 2.070
52wk Range 1.810 - 4.110
Shares Outstanding 60,533,064
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Lisata Therapeutics (NASDAQ:LSTA) Reports Narrower-Than-Expected Q3 2025 Loss ↗
Lisata Therapeutics reported a narrower-than-expected Q3 2025 loss, advancing its lead candidate, certepetide, with a cash runway into 2027. 
Via Chartmill
News headline image
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+0.5%
+0.5%
1 Month
-1.5%
-1.5%
3 Month
-18.9%
-18.9%
6 Month
-28.1%
-28.1%
1 Year
-48.2%
-48.2%

More News

Read More
News headline image
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Present at the 2025 BIO International Convention
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Announces Research License with Catalent
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Present at the Investival Showcase USA
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development
From Lisata Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Lisata Therapeutics, Inc. - Common Stock publicly traded?
Yes, Lisata Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Lisata Therapeutics, Inc. - Common Stock trade on?
Lisata Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lisata Therapeutics, Inc. - Common Stock?
The ticker symbol for Lisata Therapeutics, Inc. - Common Stock is LSTA on the Nasdaq Stock Market
What is the current price of Lisata Therapeutics, Inc. - Common Stock?
The current price of Lisata Therapeutics, Inc. - Common Stock is 1.970
When was Lisata Therapeutics, Inc. - Common Stock last traded?
The last trade of Lisata Therapeutics, Inc. - Common Stock was at 01/09/26 04:00 PM ET
What is the market capitalization of Lisata Therapeutics, Inc. - Common Stock?
The market capitalization of Lisata Therapeutics, Inc. - Common Stock is 119.25M
How many shares of Lisata Therapeutics, Inc. - Common Stock are outstanding?
Lisata Therapeutics, Inc. - Common Stock has 119M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.